SCHEMBL4606207

SCHEMBL4606207

CC(=O)Nc1ccc(CCc2ccccc2)cc1C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.56
HSD17B10 Q99714 1/20 0.56
LTC4S Q16873 1/20 0.55
METAP2 P50579 3/20 0.51
PKM P14618 2/20 0.50
ALDH1A1 P00352 2/20 0.50
MCL1 Q07820 1/20 0.50
BCL2A1 Q16548 1/20 0.50
BRD4 O60885 3/20 0.49
LMNA P02545 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
CYP2C19 P33261 2/20 0.47
POLB P06746 1/20 0.47
ABCC1 P33527 1/20 0.46
CYP19A1 P11511 1/20 0.45
MAPT P10636 1/20 0.45
CYP2C9 P11712 1/20 0.45
HPGD P15428 1/20 0.45
HTT P42858 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8887409 0.86 KDM4E (0.58) KDM4EHSD17B10LTC4SMETAP2PKM
SCHEMBL2888623 0.84 KDM4E (0.68) KDM4EHSD17B10LTC4SMETAP2PKM
SCHEMBL22762667 0.78 KDM4E (0.60) KDM4EHSD17B10PKMALDH1A1MCL1
SCHEMBL4220303 0.78 KMT2A (0.57) KDM4EHSD17B10ALDH1A1LMNASMN1; SMN2
SCHEMBL5590930 0.77 LCK (0.55) HSD17B10ALDH1A1
SCHEMBL16690904 0.76 PTPN1 (0.71) KDM4EHSD17B10MCL1CYP2C19POLB
SCHEMBL28612022 0.76 CREBBP (0.67)
SCHEMBL10489754 0.76 METAP2 (0.55) KDM4ELTC4SMETAP2PKMMCL1
SCHEMBL4219865 0.76 MPO (0.58) KDM4ELMNASMN1; SMN2ABCC1MAPT
SCHEMBL1825236 0.76 MTNR1B (0.52) KDM4EHSD17B10ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1720825-B1 ANTHRANILIC ACID DERIVATIVES, METHODS FOR THEIR PREPARATION AND USE AS DHODH INHIBITORS ACTIVE BIOTECH AB (SE) 2008-07-09 EP disclosed
US-7074831-B2 Compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB (SE) 2006-07-11 US disclosed
US-20050187297-A1 New compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB (SE) 2005-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187297-A1 New compounds, methods for their preparation and use thereof MALT1, TPMT, FUCA1 KDM4E 2898/4885HSD17B10 783/4885LTC4S 138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.